Wave Life Sciences (NASDAQ:WVE – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.
Profitability
This table compares Wave Life Sciences and Opus Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Wave Life Sciences | -66.50% | -280.57% | -52.90% |
| Opus Genetics | -324.45% | -63.65% | -56.94% |
Analyst Ratings
This is a summary of recent ratings for Wave Life Sciences and Opus Genetics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Wave Life Sciences | 0 | 1 | 7 | 1 | 3.00 |
| Opus Genetics | 0 | 0 | 1 | 0 | 3.00 |
Risk & Volatility
Wave Life Sciences has a beta of -1.07, meaning that its share price is 207% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.
Earnings & Valuation
This table compares Wave Life Sciences and Opus Genetics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Wave Life Sciences | $113.31 million | 15.69 | -$57.51 million | ($1.11) | -10.50 |
| Opus Genetics | $19.05 million | 1.79 | -$9.99 million | ($1.09) | -0.99 |
Opus Genetics has lower revenue, but higher earnings than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by insiders. Comparatively, 6.6% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Wave Life Sciences beats Opus Genetics on 8 of the 13 factors compared between the two stocks.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
